IL-6/IL-6 receptor system and its role in physiological and pathological conditions (Q37949664)

25 August 2017

title

IL-6/IL-6 receptor system and its role in physiological and pathological conditions (English)

1 reference

25 August 2017

Masahiko Mihara

1

1 reference

25 August 2017

Misato Hashizume

2

1 reference

25 August 2017

Hiroto Yoshida

3

1 reference

25 August 2017

Miho Suzuki

4

1 reference

25 August 2017

Masashi Shiina

5

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 February 2012

1 reference

25 August 2017

February 2012

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22029668

full work available at URL

15 December 2024

https://portlandpress.com/clinsci/article-pdf/122/4/143/441412/cs1220143.pdf

1 reference

15 December 2024

1 reference

25 August 2017

volume

122

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

143-159

1 reference

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Molecular cloning and expression of an IL-6 signal transducer, gp130

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

IL-6 trans-signaling: the heat is on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Recombinant soluble human interleukin-6 receptor. Expression in Escherichia coli, renaturation and purification

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Gp130 and the interleukin-6 family of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

New insights into the regulation of T cells by gamma(c) family cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

IL-6 type cytokine receptor complexes: hexamer, tetramer or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Signaling mechanisms through gp130: a model of the cytokine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

SOCS: suppressors of cytokine signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

High molecular weight hyaluronic acid inhibits IL-6-induced MMP production from human chondrocytes by up-regulating the ERK inhibitor, MKP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Central role of IL-6 receptor signal-transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

The acute phase protein response in patients receiving subcutaneous IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Impaired immune and acute-phase responses in interleukin-6-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Recent developments and complexities in neutrophil transmigration

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Transgenic blockade of interleukin 6 transsignaling abrogates inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Regulation of E‐Selectin, P‐Selectin, and Intercellular Adhesion Molecule 1 Expression in Mouse Cremaster Muscle Vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

IL-6 plays an essential role in neutrophilia under inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

IgG1 plasmacytosis in interleukin 6 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

B-cell-directed therapies for autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

The two faces of IL-6 on Th1/Th2 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Properties and origin of human Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Regulation of IL-17 in human CCR6+ effector memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Lack of evidence for an increase in interleukin-6 expression in adult murine bone, bone marrow, and marrow stromal cell cultures after ovariectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroi

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Intercellular adhesion molecule-1 on synovial cells attenuated interleukin-6-induced inhibition of osteoclastogenesis induced by receptor activator for nuclear factor κB ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin-6 inhibits early differentiation of ATDC5 chondrogenic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Desirable effect of combination therapy with high molecular weight hyaluronate and NSAIDs on MMP production

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Anemia in monkey collagen-induced arthritis is correlated with serum IL-6, but not TNFalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Severe iron deficiency anemia in transgenic mice expressing liver hepcidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin-6-deficient mice develop mature-onset obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Total cholesterol and LDL levels decrease before rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin-6 stimulates lipolysis and fat oxidation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin-6 and prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin-6 in bone metastasis and cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Molecular and cellular biology of interleukin-6 and its receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Molecular mechanisms of castration-resistant prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Cachexia worsens prognosis in patients with resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin 6 as a key regulator of muscle mass during cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Fever and hypothermia in systemic inflammation: recent discoveries and revisions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Averting inflammation by targeting the cytokine environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Interleukin-6 as a therapeutic target in candidate inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Serum amyloid A (SAA): Biochemistry, genetics and the pathogenesis of AA amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis Correlation with disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110340

Human beta 2 interferon and B-cell differentiation factor BSF-2 are identical

21 January 2018

2

1 reference

Role of interleukin 6 in fever in rats

15 December 2024

25

1 reference

15 December 2024

Amyloidosis

34

1 reference

Crohn's disease with amyloid A amyloidosis and nephrotic syndrome

15 December 2024

35

1 reference

Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis

15 December 2024

38

1 reference

Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment

15 December 2024

39

1 reference

Proinflammatory Cytokines Synergistically Enhance the Production of Chemokine Ligand 20 (CCL20) from Rheumatoid Fibroblast-like Synovial Cells in vitro and Serum CCL20 Is Reduced in vivo by Biologic Disease-modifying Antirheumatic Drugs

15 December 2024

54

1 reference

A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis

15 December 2024

58

1 reference

The effect of interleukin-6 on L-selectin levels on polymorphonuclear leukocytes

15 December 2024

60

1 reference

Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study

15 December 2024

62

1 reference

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

15 December 2024

63

1 reference

Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6

15 December 2024

69

1 reference

Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression

15 December 2024

70

1 reference

Characterization of anti-mouse interleukin-6 receptor antibody

15 December 2024

75

1 reference

Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses

15 December 2024

80

1 reference

Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis

15 December 2024

83

1 reference

The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice

15 December 2024

88

1 reference

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

15 December 2024

90

1 reference

Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways

15 December 2024

92

1 reference

Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity

15 December 2024

99

1 reference

Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy

15 December 2024

100

1 reference

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production

15 December 2024

106

1 reference

Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice

15 December 2024

108

1 reference

Interleukin-6 Regulates Human Adipose Tissue Lipid Metabolism and Leptin Productionin Vitro

15 December 2024

115

1 reference

Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis

15 December 2024

128

1 reference

Changes of cytokines and thyroid function in patients with recurrent breast cancer

15 December 2024

129

1 reference

Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker

15 December 2024

130

1 reference

Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas

15 December 2024

137

1 reference

The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1

15 December 2024

138

1 reference

Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer

15 December 2024

139

1 reference

Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL

15 December 2024

143

1 reference

Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group

15 December 2024

147

1 reference

Establishment and characterization of cachexia-inducing and -non-inducing clones of murine colon 26 carcinoma

15 December 2024

150

1 reference

Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis

15 December 2024

158

1 reference

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

15 December 2024

160

1 reference

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of s

15 December 2024

164

1 reference

Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis

15 December 2024

166

1 reference

15 December 2024

Identifiers

DOI

10.1042/CS20110340

1 reference

25 August 2017

1 reference